MOXGUARD
Intracameral Moxifloxacin ophthalmic solution — engineered for endophthalmitis prophylaxis in cataract surgery workflows.
See MOXGUARD up close.
Designed with clear labelling and surgeon-ready packaging for fast, confident identification in the operating theatre.
How MOXGUARD works
inside the anterior chamber.
Moxifloxacin targets bacterial DNA gyrase and topoisomerase IV, disrupting replication across both gram-positive and gram-negative organisms.
Intracameral Injection
MOXGUARD is injected directly into the anterior chamber at the conclusion of cataract surgery, achieving immediate high drug concentration at the surgical site.
Dual-Target Inhibition
Moxifloxacin simultaneously inhibits bacterial DNA gyrase and topoisomerase IV — two essential enzymes for bacterial DNA replication and repair.
Broad-Spectrum Coverage
Effective against common endophthalmitis pathogens including Staphylococcus, Streptococcus, and gram-negative organisms frequently encountered post-operatively.
Concentration-Dependent Activity
Delivers bactericidal concentrations well above MIC levels directly where needed — reducing dependence on patient topical compliance post-surgery.
Technical profile.
Formulated and packaged for direct integration into cataract surgery workflows.
Active Ingredient
Class
Preservative
Route
Volume
Packaging
Why surgeons trust
intracameral prophylaxis.
MOXGUARD addresses the critical need for reliable endophthalmitis prophylaxis — directly at the point of greatest vulnerability.
Endophthalmitis Prophylaxis
Intracameral antibiotic administration at the end of cataract surgery is increasingly recognized as an important step in reducing post-operative endophthalmitis risk.
ProphylacticCompliance Independent
Administered by the surgeon intraoperatively — removes the variable of patient adherence to topical antibiotic regimens during the critical early post-operative period.
Surgeon-ControlledReady-to-Use Format
Eliminates the need for pharmacy compounding — reducing the risk of dilution errors and contamination associated with preparation from topical formulations.
No CompoundingOptimized for Cataract Surgery
Designed specifically for the cataract surgical workflow — appropriate concentration, volume, and packaging for seamless integration into operative protocols.
OT-ReadyWhere MOXGUARD fits.
Integrated at the conclusion of cataract surgery — a single, controlled step before wound closure.
Incision & Access
Clear corneal incision and anterior chamber entry
Capsulorhexis
Anterior capsule opening with staining
Phacoemulsification
Cataractous lens removal and aspiration
IOL Implantation
Lens insertion into capsular bag
MOXGUARD
Intracameral moxifloxacin prophylaxis
Wound Closure
Hydration of incision and completion
Designed for the operating theatre.
Single-Dose Presentation
Individually packaged and sterilized for single-patient use to reduce cross-contamination risk.
Preservative-Free Formulation
No added preservatives — critical for intracameral administration where preservative toxicity is a concern.
Clear Labelling
Concentration and expiry prominently visible — supporting safe identification in fast-paced OT environments.
Storage Conditions
Store below 25°C, protected from light. No refrigeration required — practical for varied logistics conditions.
Interested in MOXGUARD?
Contact Agaaz Ophthalmics for detailed product information, regulatory documentation, or distribution enquiries.
MOXGUARD
Intracameral Moxifloxacin ophthalmic solution — engineered for endophthalmitis prophylaxis in cataract surgery workflows.
See MOXGUARD up close.
Designed with clear labelling and surgeon-ready packaging for fast, confident identification in the operating theatre.
How MOXGUARD works
inside the anterior chamber.
Moxifloxacin targets bacterial DNA gyrase and topoisomerase IV, disrupting replication across both gram-positive and gram-negative organisms.
Intracameral Injection
MOXGUARD is injected directly into the anterior chamber at the conclusion of cataract surgery, achieving immediate high drug concentration at the surgical site.
Dual-Target Inhibition
Moxifloxacin simultaneously inhibits bacterial DNA gyrase and topoisomerase IV — two essential enzymes for bacterial DNA replication and repair.
Broad-Spectrum Coverage
Effective against common endophthalmitis pathogens including Staphylococcus, Streptococcus, and gram-negative organisms frequently encountered post-operatively.
Concentration-Dependent Activity
Delivers bactericidal concentrations well above MIC levels directly where needed — reducing dependence on patient topical compliance post-surgery.
Technical profile.
Formulated and packaged for direct integration into cataract surgery workflows.
Active Ingredient
Class
Preservative
Route
Volume
Packaging
Why surgeons trust
intracameral prophylaxis.
MOXGUARD addresses the critical need for reliable endophthalmitis prophylaxis — directly at the point of greatest vulnerability.
Endophthalmitis Prophylaxis
Intracameral antibiotic administration at the end of cataract surgery is increasingly recognized as an important step in reducing post-operative endophthalmitis risk.
ProphylacticCompliance Independent
Administered by the surgeon intraoperatively — removes the variable of patient adherence to topical antibiotic regimens during the critical early post-operative period.
Surgeon-ControlledReady-to-Use Format
Eliminates the need for pharmacy compounding — reducing the risk of dilution errors and contamination associated with preparation from topical formulations.
No CompoundingOptimized for Cataract Surgery
Designed specifically for the cataract surgical workflow — appropriate concentration, volume, and packaging for seamless integration into operative protocols.
OT-ReadyWhere MOXGUARD fits.
Integrated at the conclusion of cataract surgery — a single, controlled step before wound closure.
Incision & Access
Clear corneal incision and anterior chamber entry
Capsulorhexis
Anterior capsule opening with staining
Phacoemulsification
Cataractous lens removal and aspiration
IOL Implantation
Lens insertion into capsular bag
MOXGUARD
Intracameral moxifloxacin prophylaxis
Wound Closure
Hydration of incision and completion
Designed for the operating theatre.
Single-Dose Presentation
Individually packaged and sterilized for single-patient use to reduce cross-contamination risk.
Preservative-Free Formulation
No added preservatives — critical for intracameral administration where preservative toxicity is a concern.
Clear Labelling
Concentration and expiry prominently visible — supporting safe identification in fast-paced OT environments.
Storage Conditions
Store below 25°C, protected from light. No refrigeration required — practical for varied logistics conditions.
Interested in MOXGUARD?
Contact Agaaz Ophthalmics for detailed product information, regulatory documentation, or distribution enquiries.
